Skip to content

Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model

Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03217942
Enrollment
20
Registered
2017-07-14
Start date
2017-07-01
Completion date
2017-10-01
Last updated
2018-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects, Hyperalgesia

Keywords

Muscle soreness, NGF-induced pain, Pain model, Long-lasting sensitization

Brief summary

The purpose of this study is to investigate and determine the time course and distribution on muscle hyperalgesia and muscle pain in a repeated, low dose NGF model. It is hypothesized that low dosages i.m injections of NGF are able to induce mechanical hyperalgesia and muscle soreness in a same manner (effect of duration) as for dosages previously used in NGF studies. Furthermore, it is also speculated if several injections of low dose NGF into the muscle combined are able to course immediate pain sensation and spreading of muscle hypersensitivity.

Detailed description

Effects of pain responses, symptom development and pattern (time course and distribution) following 5 i.m low dose injections of NGF injected into the tibialis anterior muscle will be compared to a high dose i.m injection of NGF injected into the contralateral side in healthy pain-free subjects.

Interventions

DRUGNGF

Intramuscular injection

Sponsors

Aalborg University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Double blind

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy and pain free volunteers

Exclusion criteria

* Pregnancy * Drug addiction defined as the use of cannabis, opioids or other drugs * Previous neurologic, mental illnesses, or psychiatric diseases. * Past history of chronic pain in the musculoskeletal system (muscle, joint, cartilage, connective tissue) * Participation in other pain trials throughout the study period * Lack of ability to cooperate * Taking any analgesic 24 hours before the injections * Performing any strenuous leg exercise through out the study period causing sore muscles

Design outcomes

Primary

MeasureTime frameDescription
Muscle sensitivityChange from baseline at 3 weeksPressure pain thresholds (PPTs) are assessed over the tibialis anterior muscles using a handhold pressure algometer.

Secondary

MeasureTime frameDescription
Pressure-induced referred painChange from baseline at 3 weeksAt three predetermined sites within the tibialis anterior muscle, a constant pressure stimulation (120% of PPT) is evoked by use of the pressure algometer. Subjects color their perceived sensation of pain on an electronic schematic of the lower legs using Navigate Pain.
Activity-induced muscle sorenessChange from baseline at 3 weeksSubjects perform 10 dorsiflexions with each leg. The perceived muscle soreness is reported using a numeric rating scale (NRS) and the area of soreness is colored on an electronic schematic of the lower legs (Navigate Pain).
Pain intensityAssessed continuously at 0-5 min during the injections at each legSubjects rate their perceived pain intensity on a visual analogue scale (VAS) App (Aalborg University) as displayed on a tablet computer with a sample rate of 1 Hz.
Muscle soreness DiaryChange from baseline at 3 weeksTwo times a day subjects evaluate their muscle soreness using a Likert Scale of muscle soreness for lower limp
Activity-induced muscle soreness DiaryChange from baseline at 1 weekSubjects perform 10 dorsiflexions with each leg. The perceived muscle soreness is reported using a numeric rating scale (NRS) and the area of soreness is colored on an electronic schematic of the lower legs (Navigate Pain). The activity is performed at home on days in between the sessions

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026